The Place of protease inhibitors in antiretroviral treatment
The Place of protease inhibitors in antiretroviral treatment
复制标题
DOI：
10.1590/s1413-86702009000500012
复制
发表时间：
2009-10-01
影响因子：
3.4
通讯作者：
Ferreira, P.R.A.
中科院分区：
文献类型：
--
作者：
Tenore, S.B.;Ferreira, P.R.A.
随着高效抗逆转录病毒疗法的引入，许多药物已经开发出来。关于开始使用哪种抗逆转录病毒类似物的最佳选择一直在讨论中，特别是在基于非核苷类逆转录酶抑制剂的治疗和利托那韦增强的蛋白酶抑制剂之间的选择。两者都被证明可以控制病毒复制并导致免疫增益。在非核苷类逆转录酶抑制剂和蛋白酶抑制剂作为治疗中的第三种抗逆转录病毒药物之间的选择应考虑与个体相关的因素，以及在患者的日常活动中纳入最佳治疗和潜在的依从性。以蛋白酶抑制剂为基础的治疗在各种抑制剂中显示出相似的疗效，这些抑制剂具有每种药物的不良事件的特征。对于蛋白酶耐药患者，达那韦和替普那韦疗效较好，耐药遗传屏障较高。
With the introduction of highly active antiretroviral therapy, a number of drugs have been developed. The best choice concerning which antiretroviral analogs to start is always under discussion, especially in the choice between non-nucleoside reverse transcriptase inhibitors-based therapies and ritonavir-boosted protease inhibitors. Both are proven to control viral replication and lead to immunological gain. The choice between a non-nucleoside analog reverse transcriptase inhibitor and a protease inhibitor as a third antiretroviral drug in the therapy should consider factors related to the individual, as well as the inclusion of the best therapy in the patient's daily activities and potential adherence. The protease inhibitor-based therapies showed similar efficacy among the various inhibitors with characteristics concerning the adverse events from each medicine. For the treatment of protease-resistant patients, darunavir and tipranavir showed good efficacy with higher genetic barrier to resistance.